Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

IOVANYSE / NASDAQHealthcareSmall cap

$6.90-$0.41 (-5.6%)

Last close · Data as of Nov 20, 2026

Market cap
$2.0B
P/E
-5.0x
EV / EBITDA
-5.2x
Revenue
$263.5M
Net margin
-148.4%
ROCE
-51.4%

+216.5% over the last year

Iovance Biotherapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-53.6%
3M
-23.2%
6M
+94.9%
1Y
+216.5%
5Y
Hidden
  • This period includes a one-day price step on 27 May 2022 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.41 (-5.6%) from $7 to $7 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in IOVA, bought on each weekday since 2021.

News & filings

What Iovance Biotherapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 391 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 60.6% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.

Read moreShow less

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Sector
Healthcare
Shares outstanding
411.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.0B
P/E
-5.0x
P/B
2.8x
EV / EBITDA
-5.2x
EV / Sales
7.0x
P/S
7.4x
52-week high
$14.86
52-week low
$2.14

Profitability

Operating margin
-151.1%
Net margin
-148.4%
EBITDA margin
-133.2%
ROE
-56.0%
ROCE
-51.4%
ROIC
-53.8%
ROA
-42.8%
Asset turnover
0.29

Growth

Revenue
$263.5M
Revenue growth, 1Y
60.6%
Net profit growth, 1Y
5.1%
Free cash flow
-$336.2M

Solvency

Current ratio
3.20
Debt / Equity
0.07
Debt / Assets
0.05
CFO / Net profit
0.77
Cash / Market cap
8.3%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$263.5M
Cost of revenue$173.2M
Gross profit$90.3M
Operating expenses$488.5M
Research and development$300.3M
Selling, general and administrative$152.3M
Operating income-$398.2M
Interest and other$5.2M
Pretax income-$393.1M
Tax and other-$2.1M
Net income-$391.0M

Revenue and net profit

Revenue grew 60.6% in FY2025; net profit is the dashed line.

Iovance Biotherapeutics, Inc. revenue and net profit by fiscal year
Iovance Biotherapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$395.9M
FY2023$1.2M-$444.0M
FY2024$164.1M-$372.2M
FY2025$263.5M-$391.0M

Cash flows

FY2025: -$302.4M from operations, -$336.2M free after investment (dashed).

Iovance Biotherapeutics, Inc. operating and free cash flow by fiscal year
Iovance Biotherapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$292.8M-$313.2M
FY2023-$361.8M-$384.1M
FY2024-$353.0M-$364.0M
FY2025-$302.4M-$336.2M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$263.5M+60.6%1Y
EBITDA
-$350.9M
Net profit
-$391.0M
Cash from operations
-$302.4M
Free cash flow
-$336.2M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$263.5M-$350.9M-$391.0M-$336.2M-56.0%+60.6%+5.1%

Monthly returns

Month-by-month returns of IOVA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$913.2M
Liabilities$214.6M
Equity$698.6M
Paid-in capital$3.5B
Retained earnings-$2.8B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; IOVA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Iovance Biotherapeutics, Inc. (this company)7.0x

Not shown (no positive earnings and no EV / Sales): Trevi Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Iovance Biotherapeutics, Inc.IOVAthis company$2.0B-5.0x2.8x-56.0%-5.2x
Recursion Pharmaceuticals, Inc.RXRX$2.0B-3.1x1.8x-57.0%-2.4x
Progyny, Inc.PGNY$2.0B34.1x3.9x11.3%21.2x
Omnicell, Inc.OMCL$2.0B967.3x1.6x0.2%21.5x
Trevi Therapeutics, Inc.TRVI$2.0B-46.3x10.8x-23.3%-45.9x
Ocular Therapeutix, Inc.OCUL$1.9B-7.2x2.9x-40.6%-5.1x
Harmony Biosciences Holdings, Inc.HRMY$1.9B12.0x2.2x18.2%5.2x
Astrana Health, Inc.ASTH$1.9B83.5x2.4x2.9%18.7x
Stoke Therapeutics, Inc.STOK$1.9B-272.5x5.3x-2.0%-95.4x
Peer median—4.4x2.7x-0.9%1.4x

Year-to-date ROI

IOVA since 1 January, against earlier years.

Historical volatility

IOVA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Iovance Biotherapeutics, Inc. operating margin by fiscal year
Iovance Biotherapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2023-38702.5%
FY2024-240.9%
FY2025-151.1%
LineFY2025
Cost of revenueCost Of Revenue$173.2M
Gross profitGross Profit$90.3M
Operating expensesOperating Expense$488.5M
Research and developmentResearch And Development$300.3M
Depreciation and amortisationDepreciation And Amortization In Income Statement$35.9M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$35.9M
Total expensesTotal Expenses$661.7M
Pretax incomePretax Income-$393.1M

Learn while you research

Academy chapters picked for Iovance Biotherapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing61% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →